CLSD Clearside Biomedical, Inc.
USHealthcareAs of 2026-03-12 16:00
Why CLSD matters now
Clearside Biomedical, Inc. (CLSD) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.41 with +0.00% on the session and $2.1M in market capitalization; recent performance reads 1-month -38.71% and YTD -45.33%.
The latest financial table shown here is Q3 2025, with revenue of $201.0K, net income of $-6.0M, and EPS of $-1.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1538.2%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.03
P/S
0.42
EV/EBITDA
-3.91
DCF Value
$-8.93
FCF Yield
-1538.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.6%
Operating Margin
-689.8%
Net Margin
-780.9%
ROE
55.5%
ROA
-223.3%
ROIC
-248.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201.0K | $-6.0M | $-1.14 |
| Q2 2025 | $492.0K | $-4.5M | $-0.87 |
| Q1 2025 | $2.3M | $-8.2M | $-1.65 |
| Q4 2024 | $306.0K | $-7.3M | $-1.44 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.79
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.